

Gaetano Bertino

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4577302/publications.pdf>

Version: 2024-02-01

88
papers

2,929
citations

159525

30
h-index

175177

52
g-index

90
all docs

90
docs citations

90
times ranked

4478
citing authors

#	ARTICLE	IF	CITATIONS
1	Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. <i>Gastroenterology</i> , 2018, 155, 411-421.e4.	0.6	291
2	Potential role of probiotics on colorectal cancer prevention. <i>BMC Surgery</i> , 2012, 12, S35.	0.6	180
3	Terlipressin and Albumin in Patients with Cirrhosis and Type I Hepatorenal Syndrome. <i>Digestive Diseases and Sciences</i> , 2008, 53, 830-835.	1.1	171
4	Hepatocellular Carcinoma Serum Markers. <i>Seminars in Oncology</i> , 2012, 39, 410-433.	0.8	147
5	Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. <i>Journal of Hepatology</i> , 2019, 71, 265-273.	1.8	138
6	What is changing in indications and treatment of hepatic hemangiomas. A review. <i>Annals of Hepatology</i> , 2014, 13, 327-339.	0.6	137
7	Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 688-695.	1.9	124
8	Gut microbiota in alcoholic liver disease: Pathogenetic role and therapeutic perspectives. <i>World Journal of Gastroenterology</i> , 2014, 20, 16639.	1.4	113
9	Chronic hepatitis C: This and the new era of treatment. <i>World Journal of Hepatology</i> , 2016, 8, 92.	0.8	69
10	Anorectal mucosal melanoma. <i>Oncotarget</i> , 2018, 9, 8785-8800.	0.8	68
11	Hepatocellular carcinoma and the risk of occupational exposure. <i>World Journal of Hepatology</i> , 2016, 8, 573.	0.8	67
12	Hepatocellular Carcinoma: Novel Molecular Targets in Carcinogenesis for Future Therapies. <i>BioMed Research International</i> , 2014, 2014, 1-15.	0.9	66
13	Serum Markers of Intrahepatic Cholangiocarcinoma. <i>Disease Markers</i> , 2013, 34, 219-228.	0.6	64
14	Greater severity of new onset asthma in allergic subjects who smoke: a 10-year longitudinal study. <i>Respiratory Research</i> , 2011, 12, 16.	1.4	61
15	What is changing in indications and treatment of hepatic hemangiomas. A review. <i>Annals of Hepatology</i> , 2014, 13, 327-39.	0.6	55
16	Prognostic and diagnostic value of des-gamma-carboxy prothrombin in liver cancer. <i>Drug News and Perspectives</i> , 2010, 23, 498.	1.9	52
17	Effect of pre- and post-treatment α -fetoprotein levels and tumor size on survival of patients with hepatocellular carcinoma treated by resection, transarterial chemoembolization or radiofrequency ablation: a retrospective study. <i>BMC Surgery</i> , 2014, 14, 40.	0.6	51
18	Diagnostic and prognostic value of alpha-fetoprotein, des- γ -carboxy prothrombin and squamous cell carcinoma antigen immunoglobulin M complexes in hepatocellular carcinoma. <i>Minerva Medica</i> , 2011, 102, 363-71.	0.3	48

#	ARTICLE	IF	CITATIONS
19	Circulating endothelial coagulative activation markers after smoking cessation: a 12-month observational study. <i>European Journal of Clinical Investigation</i> , 2011, 41, 616-626.	1.7	44
20	Systemic therapies in hepatocellular carcinoma: present and future. <i>Future Oncology</i> , 2013, 9, 1533-1548.	1.1	42
21	Serum markers of intrahepatic cholangiocarcinoma. <i>Disease Markers</i> , 2013, 34, 219-28.	0.6	42
22	L-carnitine supplementation improves hematological pattern in patients affected by HCV treated with Peg interferon- α 2b plus ribavirin. <i>World Journal of Gastroenterology</i> , 2011, 17, 4414.	1.4	42
23	Is Transient Elastography Needed for Noninvasive Assessment of High-Risk Varices? The REAL Experience. <i>American Journal of Gastroenterology</i> , 2019, 114, 1275-1282.	0.2	41
24	Resveratrol in Patients with Minimal Hepatic Encephalopathy. <i>Nutrients</i> , 2018, 10, 329.	1.7	38
25	A Multidisciplinary Therapeutic Approach for Reducing the Risk of Psychiatric Side Effects in Patients With Chronic Hepatitis C Treated With Pegylated Interferon α and Ribavirin. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, e210-e217.	1.1	36
26	Laparoscopic Reversal of Hartmann's Procedure: State of the Art 20 Years after the First Reported Case. <i>Gastroenterology Research and Practice</i> , 2014, 2014, 1-8.	0.7	34
27	Giant cavernous liver hemangiomas: is it the time to change the size categories?. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2016, 15, 21-29.	0.6	34
28	Real-world experience with obeticholic acid in patients with primary biliary cholangitis. <i>JHEP Reports</i> , 2021, 3, 100248.	2.6	33
29	The Supplementation of Acetyl-L-Carnitine Decreases Fatigue and Increases Quality of Life in Patients with Hepatitis C Treated with Pegylated Interferon- α 2b Plus Ribavirin. <i>Journal of Interferon and Cytokine Research</i> , 2011, 31, 653-659.	0.5	32
30	Elevated serum levels of Chromogranin A in hepatocellular carcinoma. <i>BMC Surgery</i> , 2012, 12, S7.	0.6	32
31	Psychiatric Symptoms Induced by Antiviral Therapy in Chronic Hepatitis C. <i>Clinical Drug Investigation</i> , 2006, 26, 655-662.	1.1	30
32	Carbohydrate 19.9 Antigen Serum Levels in Liver Disease. <i>BioMed Research International</i> , 2013, 2013, 1-6.	0.9	27
33	Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon- α 2b and Ribavirin Reduces Sleep Disturbance. <i>Nutrients</i> , 2017, 9, 897.	1.7	27
34	Hepatitis C Virus Infection in Children and Pregnant Women: An Updated Review of the Literature on Screening and Treatments. <i>AJP Reports</i> , 2020, 10, e121-e127.	0.4	26
35	The Immune System in Hepatocellular Carcinoma and Potential New Immunotherapeutic Strategies. <i>BioMed Research International</i> , 2015, 2015, 1-12.	0.9	25
36	Liver immunolocalization and plasma levels of MMP-9 in non-alcoholic steatohepatitis (NASH) and hepatitis C infection. <i>Acta Histochemica</i> , 2010, 112, 474-481.	0.9	23

#	ARTICLE	IF	CITATIONS
37	Silybin supplementation during HCV therapy with pegylated interferon- $\hat{1}\pm$ plus ribavirin reduces depression and anxiety and increases work ability. <i>BMC Psychiatry</i> , 2016, 16, 398.	1.1	22
38	Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon- $\hat{1}\pm 2b$ Plus Ribavirin: Effect on Work Performance. A Randomized Clinical Trial. <i>Hepatitis Monthly</i> , 2014, 14, e11608.	0.1	22
39	A study about mechanisms of des-gamma-carboxy prothrombin's production in hepatocellular carcinoma. <i>Panminerva Medica</i> , 2008, 50, 221-6.	0.2	22
40	Epoetin alpha improves the response to antiviral treatment in HCV-related chronic hepatitis. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 1055-1063.	0.8	21
41	Rosuvastatin reduces nonalcoholic fatty liver disease in patients with chronic hepatitis C treated with $\hat{1}\pm$ -interferon and ribavirin: Rosuvastatin reduces NAFLD in HCV patients. <i>Hepatitis Monthly</i> , 2011, 11, 92-8.	0.1	21
42	D-dimer plasmatic levels as a marker for diagnosis and prognosis of hepatocellular carcinoma patients with portal vein thrombosis. <i>Clinical and Experimental Gastroenterology</i> , 2018, Volume 11, 373-380.	1.0	18
43	Reduction of volumetric bone mineral density in postmenopausal women with hepatitis C virus-correlated chronic liver disease: A peripheral quantitative computed tomography (pQCT) study. <i>European Journal of Internal Medicine</i> , 2012, 23, 656-660.	1.0	15
44	Current practice of chronic hepatitis B treatment in Southern Italy. <i>European Journal of Internal Medicine</i> , 2012, 23, e124-e127.	1.0	13
45	Persistent increase in alpha-fetoprotein level in a patient without underlying liver disease who underwent curative resection of hepatocellular carcinoma. A case report and review of the literature. <i>World Journal of Surgical Oncology</i> , 2012, 10, 79.	0.8	13
46	Rare Benign Tumors of the Liver: Still Rare?. <i>Journal of Gastrointestinal Cancer</i> , 2014, 45, 202-217.	0.6	13
47	Genotype-phenotype variable correlation in Wilson disease: clinical history of two sisters with the similar genotype. <i>BMC Medical Genetics</i> , 2020, 21, 128.	2.1	13
48	Silybin-vitamin E-phospholipids complex reduces liver fibrosis in patients with chronic hepatitis C treated with pegylated interferon $\hat{1}\pm$ and ribavirin. <i>American Journal of Translational Research (discontinued)</i> , 2015, 7, 2510-8.	0.0	13
49	Carotid Intima-Media Thickness and Liver Histology in Hemodialysis Patients with Nonalcoholic Fatty Liver Disease. <i>International Journal of Angiology</i> , 2011, 20, 149-156.	0.2	12
50	Evaluation of health status in patients with hepatitis c treated with and without interferon. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 17.	1.0	12
51	Hepatitis C virus eradication by direct antiviral agents improves glucose tolerance and reduces postâ€load insulin resistance in nondiabetic patients with genotype 1. <i>Liver International</i> , 2018, 38, 1206-1211.	1.9	11
52	Rate of non-response to ursodeoxycholic acid in a large real-world cohort of primary biliary cholangitis patients in Italy. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 1274-1282.	0.6	11
53	Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESISTâ€HCV cohort. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1190-1199.	1.0	11
54	Endozepine-4 levels are increased in hepatic coma. <i>World Journal of Gastroenterology</i> , 2015, 21, 9103.	1.4	11

#	ARTICLE	IF	CITATIONS
55	Relationship between circulating interleukin-10 and histological features in patients with chronic C hepatitis. <i>Annals of Saudi Medicine</i> , 2011, 31, 360-364.	0.5	11
56	Meaning of elevated CA 19-9 serum levels in chronic hepatitis and HCV-related cirrhosis. <i>Minerva Gastroenterologica E Dietologica</i> , 2007, 53, 305-9.	2.2	11
57	Carcinoembryonic Antigen Serum Levels in Nonmelanoma Skin Cancer. <i>Biomedicines</i> , 2018, 6, 24.	1.4	10
58	Carnitine Serum Levels in Frail Older Subjects. <i>Nutrients</i> , 2020, 12, 3887.	1.7	10
59	A Lethal Complication after Transarterial Chemoembolization with Drug-Eluting Beads for Hepatocellular Carcinoma. <i>Case Reports in Surgery</i> , 2015, 2015, 1-6.	0.2	9
60	Emerging hepatic syndromes: pathophysiology, diagnosis and treatment. <i>Internal and Emergency Medicine</i> , 2016, 11, 905-916.	1.0	9
61	Hepatocellular carcinoma markers in the omics era: the glycomic analysis. <i>Hepatobiliary Surgery and Nutrition</i> , 2014, 3, 407-9.	0.7	9
62	Altered pattern of circulating matrix metalloproteinases -2,- 9 and tissue inhibitor of metalloproteinase-2 in patients with HCV-related chronic hepatitis. Relationship to histological features. <i>Panminerva Medica</i> , 2009, 51, 191-6.	0.2	9
63	Circulating erythropoietin in microalbuminuric type 2 diabetic patients with normal renal function: a pilot study. <i>Journal of Diabetes and Its Complications</i> , 2006, 20, 376-379.	1.2	7
64	Hepatocellular carcinoma: present and future. <i>Chinese Clinical Oncology</i> , 2012, 1, 14.	0.4	7
65	In chronic viral hepatitis without malignancy, abnormal serum carbohydrate 19-9 antigen levels are associated with liver disease severity and are related to different viral aetiology. <i>Digestive and Liver Disease</i> , 2010, 42, 458-459.	0.4	6
66	Some patients with HCC haven't abnormal des-gamma-carboxy prothrombin and alpha-fetoprotein levels. <i>Panminerva Medica</i> , 2009, 51, 133-4.	0.2	6
67	Individualized Treatment of Genotype 1 Na ⁺ ve Patients: An Italian Multicenter Field Practice Experience. <i>PLoS ONE</i> , 2014, 9, e110284.	1.1	5
68	Responsibility of hepatitis C virus in the development of hepatocellular carcinoma: From molecular alterations to possible solutions. <i>World Journal of Hepatology</i> , 2018, 10, 448-451.	0.8	5
69	Aberrant sialylation in a patient with a HNF1 \pm variant and liver adenomatosis. <i>IScience</i> , 2021, 24, 102323.	1.9	4
70	Homocysteine Serum Levels as Prognostic Marker of Hepatocellular Carcinoma with Portal Vein Thrombosis. <i>Current Molecular Medicine</i> , 2019, 19, 532-538.	0.6	4
71	Obesity and related diseases: an epidemiologic study in eastern Sicily. <i>Minerva Gastroenterologica E Dietologica</i> , 2006, 52, 379-85.	2.2	4
72	Blood homocysteine levels are increased in hepatocellular carcinoma patients with portal vein thrombosis. A single centre retrospective cohort study. <i>International Journal of Surgery Open</i> , 2018, 15, 60-65.	0.2	3

#	ARTICLE	IF	CITATIONS
73	High Carbohydrate 19-9 Antigen Serum Levels in Patients with Nonmelanoma Skin Cancer and Primary Occult Cancer. <i>Biomedicines</i> , 2020, 8, 265.	1.4	3
74	Improvement of health-related quality of life and psychological well-being after HCV eradication with direct-acting antiviral agents. Real life setting data of an Italian cohort valued by Hepatitis Quality of Life Questionnaire (HQLQv2). <i>Anesthesia, Intensive Care and Pain in Neonates and Children</i> , 2020, 8, 9450.	2.4	3
75	Respiratory and Cardiovascular Health Effects of e-Cigarette Substitution: Protocol for Two Living Systematic Reviews. <i>JMIR Research Protocols</i> , 2021, 10, e29084.	0.5	3
76	Serum Folate deficiency in HCV related Hepatocellular Carcinoma. <i>Scientific Reports</i> , 2022, 12, 5025.	1.6	3
77	Carotid intima-media thickness and liver histology in hemodialysis patients with nonalcoholic fatty liver disease. <i>International Journal of Angiology</i> , 2010, 19, e132-e137.	0.2	1
78	Intraoperative Identification of Biliocystic Communication Could be the Key to Avoiding Postoperative Complications Independent of the Adopted Surgical Technique to Treat Hydatid Cysts. <i>World Journal of Surgery</i> , 2015, 39, 550-551.	0.8	1
79	Job performance in chronic hepatitis C virus patients treated with pegylated interferon- α 2b plus ribavirin: an observational study. <i>Translational Medicine Communications</i> , 2017, 2, .	0.5	1
80	Telbivudine on-treatment HBsAg loss in naive HBeAg negative chronic hepatitis B: a case report and brief review of the literature. <i>Clinica Terapeutica</i> , 2012, 163, e429-34.	0.2	1
81	Delta infection in eastern Sicily. <i>European Journal of Epidemiology</i> , 1987, 3, 386-389.	2.5	0
82	Does follow-up offer the best quality of life for patients affected by so-called "giant" haemangiomas of the liver?. <i>Hpb</i> , 2015, 17, 1155.	0.1	0
83	What are the True Advantages of Devices for Hepatic Parenchymal Transection in Open Surgery?. <i>World Journal of Surgery</i> , 2015, 39, 3028-3029.	0.8	0
84	Totally Implantable Venous Access Devices: Efforts Are Needed to Standardize Procedures to Avoid Complications. <i>World Journal of Surgery</i> , 2016, 40, 1781-1782.	0.8	0
85	Folate levels in hepatocellular carcinoma patients with portal vein thrombosis. <i>BMC Gastroenterology</i> , 2020, 20, 375.	0.8	0
86	Commentary on "Insertion of Totally Implantable Central Venous Access Devices by Surgeons" - What Is the Role of Surgeons When Implanting a Totally Implantable Venous Access Device to Prevent Immediate Complications?. <i>Annals of Coloproctology</i> , 2015, 31, 163.	0.5	0
87	Assessing Degree of Hepatic Fibrosis in Patients with Chronic Liver Disease Using Gadoxetic Acid-Enhanced Liver MRI: Preliminary Results. <i>Current Medical Imaging</i> , 2016, 12, 189-195.	0.4	0
88	Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: a large, field-practice study. <i>Drugs in Context</i> , 2020, 9, 1-6.	1.0	0